Aptevo Therapeutics (APVO) Competitors

$4.63 -0.14 (-2.94%)

Closing price 05/18/2026 03:59 PM Eastern

Extended Trading

$4.61 -0.02 (-0.54%)

As of 04:14 AM Eastern

APVO vs. OTLK, AEON, TXMD, TRAW, and VYNE

Should you buy Aptevo Therapeutics stock or one of its competitors? MarketBeat compares Aptevo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptevo Therapeutics include Oncobiologics (OTLK), AEON Biopharma (AEON), TherapeuticsMD (TXMD), Traws Pharma (TRAW), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry.

How does Aptevo Therapeutics compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

In the previous week, Oncobiologics had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Oncobiologics and 2 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.72 beat Oncobiologics' score of -0.53 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

Oncobiologics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-299.23%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 2.8% of Oncobiologics shares are owned by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oncobiologics presently has a consensus price target of $4.50, indicating a potential upside of 1,863.35%. Given Oncobiologics' higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Aptevo Therapeutics has lower revenue, but higher earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	20.52	-$62.42M	-$1.17	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$1.77 thousand	N/A

Summary

Oncobiologics beats Aptevo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aptevo Therapeutics compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

AEON Biopharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, AEON Biopharma and AEON Biopharma both had 2 articles in the media. Aptevo Therapeutics' average media sentiment score of 0.72 beat AEON Biopharma's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AEON Biopharma is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$1.77 thousand	N/A

AEON Biopharma's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Summary

AEON Biopharma beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Aptevo Therapeutics compare to TherapeuticsMD?

Aptevo Therapeutics (NASDAQ:APVO) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Aptevo Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, TherapeuticsMD had 2 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 4 mentions for TherapeuticsMD and 2 mentions for Aptevo Therapeutics. TherapeuticsMD's average media sentiment score of 1.17 beat Aptevo Therapeutics' score of 0.72 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TherapeuticsMD	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TherapeuticsMD has higher revenue and earnings than Aptevo Therapeutics. TherapeuticsMD is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$1.77 thousand	N/A
TherapeuticsMD	$3.02M	7.74	-$570K	-$0.01	N/A

TherapeuticsMD has a net margin of 5.34% compared to Aptevo Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
TherapeuticsMD	5.34%	0.32%	0.23%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Aptevo Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Traws Pharma has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Traws Pharma has higher revenue and earnings than Aptevo Therapeutics. Traws Pharma is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	6.41	$9.17M	-$1.69	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$1.77 thousand	N/A

Traws Pharma currently has a consensus target price of $8.00, indicating a potential upside of 354.55%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Traws Pharma is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

8.0% of Traws Pharma shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 14.0% of Traws Pharma shares are held by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aptevo Therapeutics' return on equity of -198.50% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-913.18%	-133.88%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

In the previous week, Traws Pharma and Traws Pharma both had 2 articles in the media. Traws Pharma's average media sentiment score of 1.22 beat Aptevo Therapeutics' score of 0.72 indicating that Traws Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Traws Pharma beats Aptevo Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to VYNE Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aptevo Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -65.99% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
VYNE Therapeutics	-4,726.21%	-65.99%	-58.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 2 articles in the media. VYNE Therapeutics' average media sentiment score of 1.63 beat Aptevo Therapeutics' score of 0.72 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aptevo Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Aptevo Therapeutics has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$1.77 thousand	N/A
VYNE Therapeutics	$570K	39.53	-$26.48M	-$0.50	N/A

Summary

VYNE Therapeutics beats Aptevo Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APVO vs. The Competition

Export

Metric	Aptevo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.94M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	0.00	18.13	20.86	25.23
Price / Sales	N/A	275.96	550.91	75.54
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.27	6.57	9.67	6.63
Net Income	-$25.97M	$24.35M	$3.56B	$335.59M
7 Day Performance	-4.14%	-2.53%	-1.69%	-1.20%
1 Month Performance	-12.31%	-3.55%	-2.65%	-1.16%
1 Year Performance	-95.85%	53.51%	30.03%	28.10%

Aptevo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APVO Aptevo Therapeutics	1.3435 of 5 stars	$4.63 -2.9%	N/A	-96.0%	$5.94M	N/A	N/A	50	Earnings Report
OTLK Oncobiologics	2.4292 of 5 stars	$0.22 +2.6%	$4.50 +1,933.4%	-86.9%	$23.15M	$1.35M	N/A	20	Earnings Report Upcoming Earnings Analyst Forecast
AEON AEON Biopharma	0.8552 of 5 stars	$0.90 -1.1%	N/A	+71.6%	$23.03M	N/A	5.00	5	Upcoming Earnings Gap Up
TXMD TherapeuticsMD	0.876 of 5 stars	$1.98 -1.5%	N/A	+34.7%	$22.92M	$3.02M	N/A	420	Earnings Report High Trading Volume
TRAW Traws Pharma	3.4554 of 5 stars	$2.18 +28.2%	$8.00 +267.0%	+47.9%	$22.14M	$2.79M	2.35	17	Positive News Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptevo Therapeutics (APVO) Competitors

APVO vs. OTLK, AEON, TXMD, TRAW, and VYNE

How does Aptevo Therapeutics compare to Oncobiologics?

Summary

How does Aptevo Therapeutics compare to AEON Biopharma?

Summary

How does Aptevo Therapeutics compare to TherapeuticsMD?

Summary

How does Aptevo Therapeutics compare to Traws Pharma?

Summary

How does Aptevo Therapeutics compare to VYNE Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptevo Therapeutics (APVO) Competitors

APVO vs. OTLK, AEON, TXMD, TRAW, and VYNE

How does Aptevo Therapeutics compare to Oncobiologics?

Does the media favor OTLK or APVO?

Which has more risk and volatility, OTLK or APVO?

Is OTLK or APVO more profitable?

Do insiders & institutionals believe in OTLK or APVO?

Do analysts recommend OTLK or APVO?

Which has higher valuation & earnings, OTLK or APVO?

Summary

How does Aptevo Therapeutics compare to AEON Biopharma?

Which has more volatility and risk, AEON or APVO?

Do analysts rate AEON or APVO?

Do insiders & institutionals believe in AEON or APVO?

Does the media prefer AEON or APVO?

Which has preferable valuation & earnings, AEON or APVO?

Is AEON or APVO more profitable?

Summary

How does Aptevo Therapeutics compare to TherapeuticsMD?

Which has more volatility and risk, APVO or TXMD?

Does the media refer more to APVO or TXMD?

Do institutionals and insiders believe in APVO or TXMD?

Which has higher earnings & valuation, APVO or TXMD?

Is APVO or TXMD more profitable?

Do analysts recommend APVO or TXMD?

Summary

How does Aptevo Therapeutics compare to Traws Pharma?

Which has more risk & volatility, TRAW or APVO?

Which has better valuation & earnings, TRAW or APVO?

Do analysts rate TRAW or APVO?

Do insiders & institutionals have more ownership in TRAW or APVO?

Is TRAW or APVO more profitable?

Does the media prefer TRAW or APVO?

Summary

How does Aptevo Therapeutics compare to VYNE Therapeutics?

Do institutionals & insiders have more ownership in APVO or VYNE?

Is APVO or VYNE more profitable?

Do analysts prefer APVO or VYNE?

Does the media favor APVO or VYNE?

Which has more risk & volatility, APVO or VYNE?

Which has stronger earnings and valuation, APVO or VYNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools